Pfizer shares surge 9% on marketing and sales agreement with Mylan
Shares of drugmaker, Pfizer Ltd outperformed in an otherwise weak market. The stock of the multinational drugmaker listed on Indian exchanges rose 9% and hit an intraday high of ₹4,477 on the NSE after the company on Friday announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals Pvt Ltd.
Pfizer said it has entered into an agreement with Mylan for a period of five years to market and sell two brands Ativan and Pacitane in India. Ativan is a drug used to treat anxiety in adults and children aged 12 years and above. It also treats insomnia caused by anxiety in adults while Pacitane is indicated to treat Parkinson's disease and extrapyramidal symptoms.
"Mylan has a strong presence in the central nervous system therapy space, with skilled resources ...










